Stocks and Investing
Stocks and Investing
Tue, June 4, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, June 3, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Keay Nakae Maintained (ARWR) at Strong Buy and Held Target at $60 on, Jun 3rd, 2024
Keay Nakae of Chardan Capital, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $60 on, Jun 3rd, 2024.
Keay has made no other calls on ARWR in the last 4 months.
There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 2 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $27 on, Monday, May 13th, 2024
- Shawn Egan of "Citigroup" Maintained at Hold with Increased Target to $34 on, Wednesday, February 7th, 2024
This is the rating of the analyst that currently disagrees with Keay
- Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $50 on, Wednesday, February 7th, 2024
Contributing Sources